Tuesday, May 17, 2022 5:28:20 AM
The biotech company, Athersys, is another one of the penny stocks to watch with high short interest. It has been working on perfecting its MultiStem cell therapy product. This is its stem cell product targeting neurological, inflammatory, and immune diseases. MultiStem is being evaluated as a potential regenerative product for ischemic stroke treatment.
During the first half of the year, Athersys continued enrollment in its Phase 3 MASTERS-2 study of the MultiStem treatment and initiated new trials in Europe and Asia. The company also reached agreements with the FDA and the European Medicinal Agency on the pediatric development plan with MultiStem for the stroke program.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM